We are live on
!
Find out more
CM
CM Management Portfolio holdings
AUM
$120M
1-Year Est. Return
37.12%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$125M
AUM Growth
+$16.3M
(+15%)
Cap. Flow
+$8.43M
Cap. Flow
% of AUM
6.73%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
71
New
8
Increased
24
Reduced
9
Closed
7
Top Buys
| 1 |
Rigel Pharmaceuticals
RIGL
|
+$3.41M |
| 2 |
Talos Energy
TALO
|
+$1.71M |
| 3 |
Copa Holdings
CPA
|
+$1.58M |
| 4 |
Park Hotels & Resorts
PK
|
+$1.46M |
| 5 |
Freeport-McMoran
FCX
|
+$1.35M |
Top Sells
| 1 |
Baidu
BIDU
|
+$2.59M |
| 2 |
Alibaba
BABA
|
+$2.16M |
| 3 |
Newmark Group
NMRK
|
+$1.3M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$1.03M |
| 5 |
Hasbro
HAS
|
+$878K |
Sector Composition
| 1 | Healthcare | 39.93% |
| 2 | Materials | 10.94% |
| 3 | Technology | 9.96% |
| 4 | Industrials | 9.07% |
| 5 | Financials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Eledon Pharmaceuticals
ELDN
$299M
| $685K | 0.55% |
275,000
+115,000
| +72% | +$308K |
|
52
Lantern Pharma
LTRN
$36M
| $679K | 0.54% |
185,000
+105,000
| +131% | +$432K |
|
53
Curis
CRIS
$9.32M
| $647K | 0.52% |
6,000
| – | – |
|
54
Compass Therapeutics
CMPX
$371M
| $570K | 0.46% |
310,000
| – | – |
|
55
Edesa Biotech
EDSA
$64.2M
| $490K | 0.39% |
110,000
+20,000
| +22% | +$90.9K |
|
56
Femasys
FEMY
$9.45M
| $472K | 0.38% |
21,250
| – | – |
|
57
First Horizon
FHN
$12.3B
| $388K | 0.31% |
+25,000
| New | +$397K |
|
|
ASRT
58
DELISTED
Assertio
ASRT
| $384K | 0.31% |
21,667
-1,666
| -7% | -$33K |
|
|
PVLA
59
Palvella Therapeutics
PVLA
$2.18B
| $373K | 0.3% |
+22,500
| New | +$329K |
|
|
CADE
60
DELISTED
Cadence Bank
CADE
| $319K | 0.25% |
10,000
| – | – |
|
61
Elicio Therapeutics
ELTX
$83.3M
| $252K | 0.2% |
50,000
| – | – |
|
|
KRON
62
DELISTED
Kronos Bio
KRON
| $200K | 0.16% |
200,000
+65,000
| +48% | +$72K |
|
|
OSTX
63
OS Therapies Inc
OSTX
$65.9M
| $140K | 0.11% |
+50,000
| New | +$179K |
|
64
Cognition Therapeutics
CGTX
$85.9M
| $117K | 0.09% |
250,000
+50,000
| +25% | +$51.5K |
|
|
65
Alibaba
BABA
$276B
| – | – |
-30,000
| Closed | -$2.16M |
|
|
66
Baidu
BIDU
$37B
| – | – |
-30,000
| Closed | -$2.59M |
|
67
Gain Therapeutics
GANX
$69.5M
| – | – |
-90,000
| Closed | -$115K |
|
|
68
Hasbro
HAS
$11.5B
| – | – |
-15,000
| Closed | -$878K |
|
69
Kraft Heinz
KHC
$32B
| – | – |
-25,000
| Closed | -$806K |
|
|
VRNA
70
DELISTED
Verona Pharma
VRNA
| – | – |
-35,000
| Closed | -$506K |
|
|
RVNC
71
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-400,000
| Closed | -$1.03M |
|
Similar funds
AA
CC
DG
ACM
WAG
YMRC
IW
BCWM
CM Management's Q3 2024 Portfolio in Review
As of Q3 2024, CM Management held 71 positions worth $125M, up 15% from $109M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
CM Management deployed $8.43M of net new capital in Q3 2024, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Rigel Pharmaceuticals: 290,000 shares worth $4.69M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 36% a quarter earlier, followed by Materials and Technology.
On the sell side, the largest reduction was Newmark Group, an estimated $1.3M trimmed.
- CM Management's largest Q3 2024 buy was Rigel Pharmaceuticals: 290,000 shares worth $4.69M.
- CM Management added most to Talos Energy in Q3 2024, an estimated $1.71M increase.
- CM Management's biggest Q3 2024 reduction was Newmark Group, cutting an estimated $1.3M.
- CM Management fully exited Baidu in Q3 2024, selling an estimated $2.59M.
- CM Management's ten largest holdings make up 37% of its $125M portfolio in Q3 2024.
- CM Management opened 8 new positions and closed 7 in Q3 2024.
- CM Management's portfolio value rose 15% quarter-over-quarter to $125M.
Based on CM Management's 13F filing for Q3 2024, filed 12 Nov 2024.